Key result
Infusion of atrial natriuretic peptide (ANP) increased the circulating concentration of urodilatin 135-fold (p < 0.001) and decreased its renal clearance by 60-75% (p < 0.01) in healthy humans.
Why the study?
Does infusion of atrial natriuretic peptide increase circulating urodilatin in healthy humans?
Does infusion of atrial natriuretic peptide increase circulating urodilatin in healthy humans?
Effect estimate: 135-fold increase
p-value: p=<0.001
ANP infusion significantly increases circulating urodilatin levels and decreases its renal clearance in healthy humans, suggesting urodilatin may mediate some ANP effects.
No takes yet. Share an insight, caveat, or question.
Extends natriuretic peptide physiology in health; leaves open relevance to cardiorenal disease or therapy.
Vesely et al. (1998) studied Healthy (n=30). Atrial natriuretic peptide (ANP) infusion vs. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide was evaluated on Circulating concentration of urodilatin (135-fold increase, p=<0.001). Infusion of atrial natriuretic peptide (ANP) increased the circulating concentration of urodilatin 135-fold (p < 0.001) and decreased its renal clearance by 60-75% (p < 0.01) in healthy humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: